Tanaka, Yoshiya <br/><br/>
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.  [electronic resource] 

 -  Modern rheumatology  Jan 2018 
 - 58-65 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1439-7609 
<br/><br/><label>Standard No.: </label>10.1080/14397595.2017.1337056  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Rheumatoid--drug therapy<br/>Chemokine CX3CL1--immunology<br/>Female<br/>Humans<br/>Male<br/>Middle Aged